# Korea Otsuka Pharmaceutical Co., Ltd. trials: 42 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Korea Otsuka Pharmaceutical Co., Ltd.: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/korea-otsuka-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2024 | NCT06674291 | Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END... | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Not yet recruiting | Tuberculosis, Multidrug-Resistant | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06674291) |
| September 17, 2021 | NCT05048069 | Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab. | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Unknown | Acute Gastritis, Chronic Gastritis | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05048069) |
| December 6, 2019 | NCT04189705 | A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Acute Gastritis, Chronic Gastritis | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04189705) |
| November 4, 2019 | NCT04150172 | To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04150172) |
| November 4, 2019 | NCT04150146 | To Evaluate Food Effect on the Pharmacokinetics of Rebamipide in Healthy Volunteers | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04150146) |
| May 14, 2019 | NCT03949894 | Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic... | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 | Completed | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03949894) |
| October 17, 2018 | NCT03709017 | Iclusig PMS in CML or Ph+ALL Patients | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Unknown | Chronic Myeloid Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03709017) |
| March 19, 2018 | NCT03470233 | Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Multi-drug Resistant Tuberculosis | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03470233) |
| February 6, 2018 | NCT03423680 | A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Depression, Bipolar | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03423680) |
| January 23, 2018 | NCT03406286 | Samsca PMS in ADPKD Patients | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Safety | 2,067 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03406286) |
| December 29, 2017 | NCT03386851 | Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Schizophrenia, Bipolar 1 Disorder | 1,030 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03386851) |
| December 18, 2017 | NCT03376763 | MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical... | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 | Completed | Schizophrenia, Antipsychotics, Long-Acting Injection, LAI, Aripiprazole | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03376763) |
| March 30, 2016 | NCT02722863 | Samsca Post Marketing Surveillance Study | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Hypervolemic and Euvolemic Hyponatremia | 908 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02722863) |
| February 2, 2015 | NCT02352285 | Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 | Terminated | Heart Failure With Hyponatremia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02352285) |
| September 26, 2014 | NCT02250170 | Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Completed | Solid Tumor | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02250170) |
| March 21, 2014 | NCT02094469 | Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Vasospastic Angina | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02094469) |
| March 14, 2014 | NCT02087007 | A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Vasospastic Angina | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02087007) |
| September 13, 2013 | NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka... | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Terminated | Advanced Hepatocellular Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01942083) |
| August 19, 2013 | NCT01925521 | OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01925521) |
| February 20, 2013 | NCT01795105 | ABF Tourette's Disorder Post Marketing Surveillance Study | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Tourette's Disorder | 692 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01795105) |
| February 4, 2013 | NCT01782833 | Pletaal SR Post Marketing Observational Study | Korea Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Ischemic Symptoms, Cerebral Infarction | 3,635 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01782833) |
| November 15, 2012 | NCT01726816 | Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 2 | Completed | Diabetic Nephropathy | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01726816) |
| October 22, 2012 | NCT01711333 | A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to... | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 | Completed | Chronic Occlusive Arterial Disease | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01711333) |
| March 13, 2012 | NCT01552590 | Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 | Terminated | Hyponatremia and Extracellular Fluid in Cirrhotic | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01552590) |
| October 3, 2011 | NCT01444885 | Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 2 | Completed | Variant Angina | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01444885) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 2 | 3 |
| Phase 3 | 8 |
| Phase 4 | 12 |
| Observational | 12 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Unknown | 5 |
| Terminated | 3 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 5 |
| Bipolar Disorder | 4 |
| Arthritis, Rheumatoid | 3 |
| Angina Pectoris, Variant | 3 |
| Cerebral Infarction | 3 |
| Tourette Syndrome | 2 |
| Tuberculosis, Multidrug-Resistant | 2 |
| Psychotic Disorders | 1 |
| Tic Disorders | 1 |
| Hyponatremia | 1 |
| Polycystic Kidney, Autosomal Dominant | 1 |
| Osteoarthritis | 1 |
| Spondylitis, Ankylosing | 1 |
| Stomatitis | 1 |
| Diabetic Nephropathies | 1 |
| Peripheral Arterial Disease | 1 |
| Coronary Artery Disease | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Spanish restaurants in the United States](https://specstream.ai/data/businesses/spanish-restaurants/united-states)
- [Backflow companies in the United States](https://specstream.ai/data/businesses/backflow-companies/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Montessori schools in the United States](https://specstream.ai/data/businesses/montessori-schools/united-states)
- [T-shirt printers in the United States](https://specstream.ai/data/businesses/t-shirt-printers/united-states)
